Last reviewed · How we verify

Engerix B Hepatitis B Vaccine — Competitive Intelligence Brief

Engerix B Hepatitis B Vaccine (Engerix B Hepatitis B Vaccine) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Hepatitis B vaccine. Area: Immunology.

phase 3 Hepatitis B vaccine Hepatitis B surface antigen (HBsAg) Immunology Biologic Live · refreshed every 30 min

Target snapshot

Engerix B Hepatitis B Vaccine (Engerix B Hepatitis B Vaccine) — Tel-Aviv Sourasky Medical Center. Engerix B stimulates the immune system to produce antibodies against hepatitis B surface antigen, conferring protection against hepatitis B virus infection.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Engerix B Hepatitis B Vaccine TARGET Engerix B Hepatitis B Vaccine Tel-Aviv Sourasky Medical Center phase 3 Hepatitis B vaccine Hepatitis B surface antigen (HBsAg)
Engerix-B Kinder Engerix-B Kinder GlaxoSmithKline marketed Recombinant hepatitis B vaccine Hepatitis B surface antigen (HBsAg)
Vaccin GenHevac B Pasteur Vaccin GenHevac B Pasteur Central Hospital, Nancy, France marketed Recombinant hepatitis B vaccine Hepatitis B surface antigen (HBsAg)
HBV-MPL vaccine (208129) HBV-MPL vaccine (208129) GlaxoSmithKline phase 3 Recombinant hepatitis B vaccine with adjuvant Hepatitis B surface antigen (HBsAg); TLR4 (via MPL adjuvant)
Henogen HB vaccine Henogen HB vaccine Henogen phase 3 Recombinant hepatitis B vaccine Hepatitis B surface antigen (HBsAg)
Fendrix vaccine Fendrix vaccine Henogen phase 3 Recombinant hepatitis B vaccine with adjuvant Hepatitis B surface antigen (HBsAg)
Engerix B® Pediatric Engerix B® Pediatric Sanofi Pasteur, a Sanofi Company phase 3 Recombinant hepatitis B vaccine Hepatitis B surface antigen (HBsAg)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Hepatitis B vaccine class)

  1. Merck Sharp & Dohme LLC · 1 drug in this class
  2. Tel-Aviv Sourasky Medical Center · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Engerix B Hepatitis B Vaccine — Competitive Intelligence Brief. https://druglandscape.com/ci/engerix-b-hepatitis-b-vaccine. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: